Alex Crowe

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. pmc Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening
    Alex Crowe
    Center for Neurodegenerative Disease Research, Institute on Aging, and Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biochemistry 48:7732-45. 2009
  2. pmc High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation
    Alex Crowe
    Center for Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Biochem Biophys Res Commun 358:1-6. 2007
  3. pmc Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation
    Alex Crowe
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 288:11024-37. 2013
  4. doi request reprint Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties
    Carlo Ballatore
    Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, PA 19104 6323, USA
    Bioorg Med Chem 20:4451-61. 2012
  5. pmc Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors
    Kurt R Brunden
    Center for Neurodegenerative Disease Research, Institute on Aging, and Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Exp Neurol 223:304-10. 2010
  6. pmc Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation
    Carlo Ballatore
    Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104 6323, USA
    J Med Chem 53:3739-47. 2010
  7. pmc Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau
    Wenkai Li
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 94305, USA
    J Neurochem 110:1339-51. 2009
  8. ncbi request reprint Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual
    Vivianna M Van Deerlin
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research and Institute on Aging, University of Pennsylvania, 3600 Spruce St, 3 Maloney Bldg, Philadelphia, PA, 19104, USA
    Acta Neuropathol 113:471-9. 2007
  9. ncbi request reprint An English kindred with a novel recessive tauopathy and respiratory failure
    David J Nicholl
    Department of Neurology, City Hospital, University of Birmingham, Birmingham B18 7QH, UK
    Ann Neurol 54:682-6. 2003

Detail Information

Publications9

  1. pmc Identification of aminothienopyridazine inhibitors of tau assembly by quantitative high-throughput screening
    Alex Crowe
    Center for Neurodegenerative Disease Research, Institute on Aging, and Department of Pathology and Laboratory Medicine, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    Biochemistry 48:7732-45. 2009
    ..Thus, the ATPZ molecules described here represent a novel class of tau assembly inhibitors that merit further development for testing in animal models of AD-like tau pathology...
  2. pmc High throughput screening for small molecule inhibitors of heparin-induced tau fibril formation
    Alex Crowe
    Center for Neurodegenerative Disease Research, Institute on Aging, University of Pennsylvania, 3600 Spruce Street, Philadelphia, PA 19104, USA
    Biochem Biophys Res Commun 358:1-6. 2007
    ..This study delineates focused strategies for HTS of tau fibrillization inhibitors that are relevant to drug discovery for Alzheimer's disease and related tauopathies...
  3. pmc Aminothienopyridazines and methylene blue affect Tau fibrillization via cysteine oxidation
    Alex Crowe
    Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA
    J Biol Chem 288:11024-37. 2013
    ..These findings reveal that the ATPZs and methylene blue act by a mechanism that may affect their viability as potential therapeutic agents...
  4. doi request reprint Aminothienopyridazine inhibitors of tau aggregation: evaluation of structure-activity relationship leads to selection of candidates with desirable in vivo properties
    Carlo Ballatore
    Department of Chemistry, University of Pennsylvania, 231 South 34th Street, Philadelphia, PA 19104 6323, USA
    Bioorg Med Chem 20:4451-61. 2012
    ..The latter studies revealed that this compound is well-tolerated with no notable side-effects at an oral dose of 50mg/kg/day...
  5. pmc Tau-directed drug discovery for Alzheimer's disease and related tauopathies: a focus on tau assembly inhibitors
    Kurt R Brunden
    Center for Neurodegenerative Disease Research, Institute on Aging, and Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Exp Neurol 223:304-10. 2010
    ..We briefly review recent advances in tau-based drug discovery, with an emphasis on the identification of compounds that inhibit the assembly of tau into multimers and fibrils...
  6. pmc Discovery of brain-penetrant, orally bioavailable aminothienopyridazine inhibitors of tau aggregation
    Carlo Ballatore
    Department of Chemistry, School of Arts and Sciences, University of Pennsylvania, 231 South 34th Street, Philadelphia, Pennsylvania 19104 6323, USA
    J Med Chem 53:3739-47. 2010
    ..Taken together, these results suggest that examples from the ATPZ class hold promise as candidates for in vivo efficacy studies in animal models of neurodegenerative tauopathies...
  7. pmc Inhibition of tau fibrillization by oleocanthal via reaction with the amino groups of tau
    Wenkai Li
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 94305, USA
    J Neurochem 110:1339-51. 2009
    ..These findings provide a potential scheme for the development of novel therapies for neurodegenerative tauopathies...
  8. ncbi request reprint Biochemical and pathological characterization of frontotemporal dementia due to a Leu266Val mutation in microtubule-associated protein tau in an African American individual
    Vivianna M Van Deerlin
    Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease Research and Institute on Aging, University of Pennsylvania, 3600 Spruce St, 3 Maloney Bldg, Philadelphia, PA, 19104, USA
    Acta Neuropathol 113:471-9. 2007
    ..This is also the first reported case of any MAPT mutation in an individual of African American ethnicity...
  9. ncbi request reprint An English kindred with a novel recessive tauopathy and respiratory failure
    David J Nicholl
    Department of Neurology, City Hospital, University of Birmingham, Birmingham B18 7QH, UK
    Ann Neurol 54:682-6. 2003
    ..This disorder showed extensive tau neuropathology, and both had a novel homozygous S352L tau gene mutation. This is the first description of a pathologically proved young-onset tauopathy with apparent recessive inheritance...